Compare CubeSmart (CUBE) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CubeSmart vs Cassava Sciences Inc — how do they compare? CubeSmart trades at $37.97 (market cap $8.45B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: CubeSmart is far larger — about 214.5× Cassava Sciences Inc's market cap, and CubeSmart pays a 5.65% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CubeSmart for 89 Days and Cassava Sciences Inc for 37 Days on average.
| CUBE | FLNA | |
|---|---|---|
Market Cap | $8.45B | $39.40M |
Volume | 2,879,532 | 759,018 |
Sector | Real Estate | Health |
52-Week High | $42.50 | $4.64 |
52-Week Low | $35.36 | $0.68 |
Typical Hold Time | 89 Days | 37 Days |
Enterprise Value | $11.97B | -$43.28M |
Dividend Yield | 5.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CubeSmart (CUBE) trades at $37.51, up 0.75% with mixed technical signals showing bearish moving averages but neutral oscillators. The REIT maintains strong profitability with 29.41% net margins and has beaten earnings estimates in two of the last three quarters. Recent institutional activity shows both acquisitions and reductions in positions, while analyst consensus leans toward Hold with a $44 price target representing 17% upside potential.
CUBE presents a balanced opportunity with attractive dividend yield and improving operational trends, though elevated leverage and moderating same-store NOI growth pose risks. The stock trades at reasonable valuations relative to sector peers, with potential catalysts from supply normalization and AI-driven real estate demand. Key risks include interest rate sensitivity and competitive pressures in the self-storage sector.
FLNA trades at $0.8136, down 0.26% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates in recent quarters. Recent positive news includes FDA lifting a clinical hold on its epilepsy drug, enabling Phase 2a studies.
The outlook remains high-risk due to persistent negative cash flows and lack of revenue, but analyst consensus is bullish with 67% buy ratings. Key risks include clinical trial execution and funding needs, while the FDA decision provides a potential catalyst for long-term investors focused on biotech turnaround stories.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
